Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), is the leader in transcatheter structural heart valvular therapies in China. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease.
Venus Medtech is founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang). In 2014, the New Bioprosthetic Aortic Valve Project gained the company a national champion in the biomedicine sector and brought the company to prominence. Our impressive progress is marked by multiple industry-first achievements: the first TAVR product approved in China, the first retrievable TAVR product approved in China, the first self-expanding TPVR product approved in China and Europe, the first Class III implantable cardiovascular device approved under the CE new MDR. On December 10th, 2019, Venus Medtech was successfully listed on the Main Board of the Hong Kong Stock
Exchange (stock code: 2500.HK).
The company has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertensive renal denervation (RDN) therapy and relevant accessory products. As of June 2024, our product pipeline comprised ten innovative devices, addressing valvular heart diseases, interventional hypertension treatment, and other areas. We have commercialized three TAVR products (VenusA-Valve, VenusA-Plus and VenusA-Pro), one TPVR product (VenusP-Valve), and two procedural accessories (expandable catheter sheath product G Sheath and balloon catheter TAV0). Clinical trials are underway for our next-generation dry-valve TAVR products (Venus-Vitae and Venus-PowerX), as well as innovative medical device Cardiovalve for both TMVR and TTVR. Outside of valvular diseases, we are at the forefront of developing innovative RDN devices for the interventional treatment of hypertension.
Taking a pragmatic approach to innovation, we strive to build a strong portfolio of core technologies. As of December 2023, the company had a total of 800+ patents and patents under application, including 400+ authorized invention patents. Our global intellectual property portfolio covers China, United States, Europe, Japan, Canada, Russia, India, Brazil and other countries and regions. As a trailblazing innovator, Venus Medtech enjoys a wealth of awards and honors, including undertaking the National Science and Technology Support Program under the 12th Five-Year Development Plan and National Key Research and Development Program under the 13th Five-Year Development Plan initiated by the Ministry of Science and Technology of China, the second batch of State-Level Technologically Advanced Little Giant Enterprises, China Outstanding Patent Award, Excellent Domestic Medical Equipment Products, and National High-Tech Enterprise.
Dedicated to shaping and optimizing national medical device standards, we drive the industry toward continuous upgrades and high-quality development. As of September 2024, Venus Medtech led or participated in the drafting of nearly 10 relevant standards, of which two national and industry standards and four social organization standards have been released, including General Requirements for Animal-Derived Pericardial Leaflets, Standard Test Methods for Durability Testing of Heart Valve Substitutes Implanted by Transcatheter Techniques, Transcatheter Implantable Pulmonary Valve Substitute, etc.
Driven by innovation, we will be further committed to the development and commercialization of novel devices for structural heart therapies, accelerating the global reach of our innovations. Going forward, the company will continue to focus on structural heart valve therapies, providing comprehensive solutions for all four heart valves. Maintaining an open and collaborative mindset, we will continue to explore frontier technologies, address critical clinical challenges, and work in concert with the global medical community to advance innovative therapies in interventional cardiology.
First Prize of Technological Invention Award - Guangdong Science and Technology Awards 2023
Oct 2024— Guangdong Provincial People's GovernmentFirst Prize of Science and Technology Progress Award - Shanghai Science and Technology Awards 2023
Oct 2024— Shanghai Municipal People's GovernmentHigh-value patent project in interventional cardiovascular medical devices included in Zhejiang’s inaugural list of high-value patent cultivation projects and bases
Aug 2024— Zhejiang Provincial Intellectual Property Office“THV Solutions” included in Zhejiang’s first Major Technological Achievements Promotion List under the Large-scale Equipment Renewal and Consumer Goods Trade-in Initiative
Aug 2024— Zhejiang Provincial Department of Science and TechnologyCardiovalve Ltd., a Venus Medtech company, received “CIC Star Company of the Year 2023 - Frontier Therapies”
May 2024— China Insights ConsultancyMultiple Venus Medtech products included in the Candidate Products for 2024 Hangzhou High-Quality Product Recommendation Directory
May 2024— Hangzhou Bureau of Economy and Information TechnologyLittle Giant Firm in Technology, Zhejiang Province
Nov 2023— Zhejiang Provincial Department of Science and TechnologyBest ESG Innovation Award
Nov 2023— Zhitong FinanceBiomedical Materials Best Project (First Batch)
Sep 2023— Ministry of Information and TechnologyBest International Strategy for China Medical Device Enterprise Going Global
Jul 2023— 2023 China-Go-Global Medical Device ConferenceNational Key Technology Research and Development Program for the 14th Five-Year Period
Nov 2022— High Technology Research and Development Center, Ministry of Science and Technology of ChinaNational Key Laboratory
Nov 2022— Zhejiang Provincial Department of Science and TechnologyExcellent R&D Team
Jun 2021— Hangzhou Municipal New Economic and New Social Organizations Working Committee, Hangzhou Digital Economy Comprehensive CommitteeFirst Prize of the Technical Invention Award of the Excellent Achievements in Scientific Research (Science and Technology) of Higher Education
Mar 2021— Ministry of EducationKey Laboratory for Quality Research and Control of Tissue Regeneration Biomaterials
Feb 2021— National Medical Products Administration (NMPA)2020 Zhejiang Province Trademark Brand Strategy Demonstration Enterprise
Jan 2021— Zhejiang Provincial Administration for Market Regulation2020 China Big Health Industry Trend List - Excellence Enterprise of the Medical Device
Jan 2021— 21st Century Business HeraldThe 5th Annual Golden Hong Kong Stock Awards - Best Pharmaceutical and Medical Company
Jan 2021— Zhitong Finance, Tonghuashun Finance2020 Hangzhou Patent Pilot Enterprise
Nov 2020— Hangzhou Municipal Administration of Market RegulationSecond Batch of State-Level Technologically Advanced Little Giant Enterprises
Nov 2020— Office of Small and Medium-sized Enterprises, Ministry of Industry and Information Technology2020 Top 500 New Economy Enterprise in China
Nov 2020— China Enterprise Evaluation Association2020 Excellent Industrial Product in Zhejiang Province
Sep 2020— Zhejiang Excellent Industrial Products Selection CommitteeExcellent Domestic Medical Equipment Products
Sep 2020— China Association of Medical EquipmentChina Patent Excellence Award
Jul 2020— China National Intellectual Property Administration3rd Phoenix Award for Top 10 IPOs in Zhejiang Province
Mar 2020— Zhejiang Investment and M&A Association2019 Gazelle Company
Mar 2020— Hangzhou High-tech Development Zone (Binjiang) Bureau of Economy and Information TechnologySichuan Provincial Science and Technology Progress Award (Development and popularization of transcatheter aortic valve implantation device)
Feb 2020— Sichuan Provincial People's Government2020 Top 50 Private Enterprises for Multinational Operations in Zhejiang
Jan 2020— Zhejiang Institute of Multinational Corporations, Zhejiang Outbound Investment Enterprises AssociationNational High-Tech Enterprise
Dec 2019— Science Technology Department of Zhejiang ProvinceZhejiang Provincial Key Laboratory for Implantable and Interventional Right Heart Devices
Nov 2019— Science Technology Department of Zhejiang Province2018 Gazelle Company
Jul 2019— Hangzhou High-tech Development Zone (Binjiang) Bureau of Economy and Information TechnologyWell-Known Trademark in Zhejiang
Jan 2019— Zhejiang Provincial Administration for Market RegulationEngineering Research Center for Functional Materials for Cardiovascular Applications in Zhejiang Province
Jan 2019— Zhejiang Provincial Development and Reform CommissionHangzhou Enterprise Technology Center
Jan 2019— Hangzhou Science and Technology BureauLeading Medical Devices Brand in China
Sep 2018— Office of China Consumption and Economy Forum, Consumption DailyNational Science and Technology Support Program Award under the 13th Five-Year Development Plan
Apr 2017— Ministry of Science and Technology of ChinaLeading Team for Innovation and Entrepreneurship
Apr 2016— Science Technology Department of Zhejiang ProvinceKey Enterprise Research Institute for TVR Product Development Project
Apr 2014— Science Technology Department of Zhejiang ProvinceNational Science and Technology Support Program Award under the 12th Five-Year Development Plan
Apr 2014— Ministry of Science and Technology of ChinaChampion in Biomedicine, 3rd China Innovation and Entrepreneurship Competition
Apr 2014— Ministry of Science and Technology of ChinaFirst Prize of Technological Invention Award - Guangdong Science and Technology Awards 2023
Oct 2024 — Guangdong Provincial People's GovernmentFirst Prize of Science and Technology Progress Award - Shanghai Science and Technology Awards 2023
Oct 2024 — Shanghai Municipal People's GovernmentHigh-value patent project in interventional cardiovascular medical devices included in Zhejiang’s inaugural list of high-value patent cultivation projects and bases
Aug 2024 — Zhejiang Provincial Intellectual Property Office“THV Solutions” included in Zhejiang’s first Major Technological Achievements Promotion List under the Large-scale Equipment Renewal and Consumer Goods Trade-in Initiative
Aug 2024 — Zhejiang Provincial Department of Science and TechnologyCardiovalve Ltd., a Venus Medtech company, received “CIC Star Company of the Year 2023 - Frontier Therapies”
May 2024 — China Insights ConsultancyMultiple Venus Medtech products included in the Candidate Products for 2024 Hangzhou High-Quality Product Recommendation Directory
May 2024 — Hangzhou Bureau of Economy and Information TechnologyExcellent R&D Team
Jun 2021 — Hangzhou Municipal New Economic and New Social Organizations Working Committee, Hangzhou Digital Economy Comprehensive CommitteeFirst Prize of the Technical Invention Award of the Excellent Achievements in Scientific Research (Science and Technology) of Higher Education
Mar 2021 — Ministry of EducationKey Laboratory for Quality Research and Control of Tissue Regeneration Biomaterials
Feb 2021 — National Medical Products Administration (NMPA)2020 Zhejiang Province Trademark Brand Strategy Demonstration Enterprise
Jan 2021 — Zhejiang Provincial Administration for Market Regulation2020 China Big Health Industry Trend List - Excellence Enterprise of the Medical Device
Jan 2021 — 21st Century Business HeraldThe 5th Annual Golden Hong Kong Stock Awards - Best Pharmaceutical and Medical Company
Jan 2021 — Zhitong Finance, Tonghuashun Finance2020 Hangzhou Patent Pilot Enterprise
Nov 2020 — Hangzhou Municipal Administration of Market RegulationSecond Batch of State-Level Technologically Advanced Little Giant Enterprises
Nov 2020 — Office of Small and Medium-sized Enterprises, Ministry of Industry and Information Technology2020 Top 500 New Economy Enterprise in China
Nov 2020 — China Enterprise Evaluation Association2020 Excellent Industrial Product in Zhejiang Province
Sep 2020 — Zhejiang Excellent Industrial Products Selection CommitteeExcellent Domestic Medical Equipment Products
Sep 2020 — China Association of Medical EquipmentChina Patent Excellence Award
Jul 2020 — China National Intellectual Property Administration3rd Phoenix Award for Top 10 IPOs in Zhejiang Province
Mar 2020 — Zhejiang Investment and M&A Association2019 Gazelle Company
Mar 2020 — Hangzhou High-tech Development Zone (Binjiang) Bureau of Economy and Information TechnologySichuan Provincial Science and Technology Progress Award (Development and popularization of transcatheter aortic valve implantation device)
Feb 2020 — Sichuan Provincial People's Government2020 Top 50 Private Enterprises for Multinational Operations in Zhejiang
Jan 2020 — Zhejiang Institute of Multinational Corporations, Zhejiang Outbound Investment Enterprises AssociationNational High-Tech Enterprise
Dec 2019 — Science Technology Department of Zhejiang ProvinceZhejiang Provincial Key Laboratory for Implantable and Interventional Right Heart Devices
Nov 2019 — Science Technology Department of Zhejiang Province2018 Gazelle Company
Jul 2019 — Hangzhou High-tech Development Zone (Binjiang) Bureau of Economy and Information TechnologyWell-Known Trademark in Zhejiang
Jan 2019 — Zhejiang Provincial Administration for Market RegulationEngineering Research Center for Functional Materials for Cardiovascular Applications in Zhejiang Province
Jan 2019 — Zhejiang Provincial Development and Reform CommissionHangzhou Enterprise Technology Center
Jan 2019 — Hangzhou Science and Technology BureauLeading Medical Devices Brand in China
Sep 2018 — Office of China Consumption and Economy Forum, Consumption DailyNational Science and Technology Support Program Award under the 13th Five-Year Development Plan
Apr 2017 — Ministry of Science and Technology of ChinaLeading Team for Innovation and Entrepreneurship
Apr 2016 — Science Technology Department of Zhejiang ProvinceKey Enterprise Research Institute for TVR Product Development Project
Apr 2014 — Science Technology Department of Zhejiang ProvinceNational Science and Technology Support Program Award under the 12th Five-Year Development Plan
Apr 2014 — Ministry of Science and Technology of ChinaChampion in Biomedicine, 3rd China Innovation and Entrepreneurship Competition
Apr 2014 — Ministry of Science and Technology of China